title: Health utilities in relation to treatment response and adverse events in relapsed/refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
abstract: New therapies for relapsing/refractory Hodgkin lymphoma (R/R HL) and R/R systemic anaplastic large-cell lymphoma (sALCL) have emerged. This study captured utility values for R/R HL and sALCL to support economic evaluation. Health state "vignettes" were developed describing states associated with R/R HL and sALCL: treatment response (complete or partial response), stable and progressive disease and treatment-related adverse events (B-symptoms, acute/chronic graft-versus-host disease [GVHD] and peripheral neuropathy). Vignettes were evaluated by members of the public in the UK, Australia, Taiwan, Thailand, South Korea, Brazil and Mexico using the time trade-off method. Mean utilities varied substantially. Complete response utility scores were UK: 0.906, Australia: 0.889, Taiwan: 0.597, Thailand: 0.728, South Korea: 0.827, Brazil: 0.764, Mexico: 0.728. Adverse events were associated with disutility: acute GVHD, lowest mean utility value: Thailand 0.124; highest value: Mexico 0.467. Societal evaluation of health states for R/R HL and sALCL revealed a marked perceived benefit of a treatment response.
authors.affiliation: ICON, Patient Reported Outcomes , Oxford , UK.
authors.forename: Paul
authors.initials: P
authors.lastname: Swinburn
authors.forename: Sarah
authors.initials: S
authors.lastname: Shingler
authors.forename: Sarah
authors.initials: S
authors.lastname: Acaster
authors.forename: Andrew
authors.initials: A
authors.lastname: Lloyd
authors.forename: Vijayveer
authors.initials: V
authors.lastname: Bonthapally
mesh_terms: D000328:Adult; D001315:Australia; D001938:Brazil; D005260:Female; D006296:Health Services / Q000706:statistics & numerical data*; D006306:Health Surveys / Q000379:methods / Q000706:statistics & numerical data*; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D017728:Lymphoma, Large-Cell, Anaplastic / Q000628:therapy*; D008297:Male; D008800:Mexico; D008875:Middle Aged; D017063:Outcome Assessment, Health Care / Q000379:methods / Q000706:statistics & numerical data*; D011788:Quality of Life; D019057:Quality-Adjusted Life Years; D056910:Republic of Korea; D011795:Surveys and Questionnaires; D013624:Taiwan; D013785:Thailand; D006113:United Kingdom; D055815:Young Adult
keywords: Hodgkin lymphoma; adverse events; anaplastic large cell lymphoma; cost-effectiveness; economic evaluation; utilities